These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2178361)

  • 1. Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma--an overview.
    d'Arville CN; Johnson PJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1007-12. PubMed ID: 2178361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone.
    Forbes A; Wilkinson ML; Iqbal MJ; Johnson PJ; Williams R
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1659-64. PubMed ID: 2828073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Apropos of a letter by Mal et al.: Treatment of 25 patients with hepatocellular carcinoma with an antiandrogen, cyproterone acetate (Androcur)].
    Schlumberger JF
    Gastroenterol Clin Biol; 1987 Nov; 11(11):835. PubMed ID: 2828143
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas.
    Yu L; Nagasue N; Makino Y; Nakamura T
    J Hepatol; 1995 Mar; 22(3):295-302. PubMed ID: 7608480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal treatment of human hepatocellular carcinoma.
    Di Maio M; De Maio E; Morabito A; D'Aniello R; De Feo G; Gallo C; Perrone F
    Ann N Y Acad Sci; 2006 Nov; 1089():252-61. PubMed ID: 17261772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of growth and induction of TGF-beta 1 in human hepatocellular carcinoma with androgen receptor by cyproterone acetate in male nude mice.
    Nagasue N; Yu L; Yamaguchi M; Kohno H; Tachibana M; Kubota H
    J Hepatol; 1996 Oct; 25(4):554-62. PubMed ID: 8912156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
    Tan CK; Chow PK; Findlay M; Wong C; Machin D
    J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma.
    Guéchot J; Peigney N; Ballet F; Vaubourdolle M; Giboudeau J; Poupon R
    Hepatology; 1989 Sep; 10(3):346-8. PubMed ID: 2547704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.
    Grimaldi C; Bleiberg H; Gay F; Messner M; Rougier P; Kok TC; Cirera L; Cervantes A; De Greve J; Paillot B; Buset M; Nitti D; Sahmoud T; Duez N; Wils J
    J Clin Oncol; 1998 Feb; 16(2):411-7. PubMed ID: 9469323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?
    Pignata S; Daniele B; Gallo C; De Vivo R; Monfardini S; Perrone F
    Eur J Cancer; 1998 Jan; 34(1):25-32. PubMed ID: 9624234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and medical treatment of hepatocellular carcinoma (HCC).
    Rougier P; Mitry E; Clavero-Fabri MC
    Hepatogastroenterology; 1998 Aug; 45 Suppl 3():1264-6. PubMed ID: 9730386
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormonal treatment of hepatocellular carcinoma.
    Wilkinson ML; Forbes A
    J Hepatol; 1992 Mar; 14(2-3):406-7. PubMed ID: 1323605
    [No Abstract]   [Full Text] [Related]  

  • 13. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment?
    Boix L; Bruix J; Castells A; Fuster J; Bru C; Visa J; Rivera F; Rodes J
    J Hepatol; 1993 Feb; 17(2):187-91. PubMed ID: 8383159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between sex hormones and hepatocellular carcinoma.
    El Mahdy Korah T; Abd Elfatah Badr E; Mohamed Emara M; Ahmed Samy Kohla M; Gamal Saad Michael G
    Andrologia; 2016 Nov; 48(9):948-955. PubMed ID: 26791111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma and sex hormones.
    Nagasue N; Kohno H
    HPB Surg; 1992; 6(1):1-6. PubMed ID: 1334694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib.
    Chu YD; Lin KH; Huang YH; Lin CC; Hung CF; Yeh TS; Lee WC; Yeh CT
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e341-e351. PubMed ID: 29785761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
    Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
    Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.